

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

10 Jun 2026

### The effect of donor bone marrow cells infusion on chimerism and prognosis of kidney allograft outcomes.

#### Protocol summary

##### Summary

Infusion of donor CD34+ progenitor cells concurrent with organ transplantation is one of the most effective protocols for induction and/or augmentation of post-transplant chimerism. The aim of our study was to investigate the effect of donor bone marrow cells infusion (DBMI) on chimerism augmentation and outcome of allograft in renal transplant recipients from living unrelated donors (LURD). A randomized controlled trial, without placebo, not blinded and single center study was performed on 40 kidney allograft recipients consisted of 20 patients with DBMI (100-150 ml of isolated mononuclear cells from donor bone marrow sample) and 20 patients without infusion; the patients were monitored prospectively for two years. Informed consent was obtained from all donors and recipients according to protocols approved by Tehran University of Medical Sciences Ethics Committee. Inclusion criterion was: being the case for first renal transplantation and exclusion criteria were: having genetic, cardiovascular diseases; previous transfusion, re-transplantation and morbid obesity. Both groups received the same baseline immunosuppressant; consist of triple drug regimen; cyclosporine A, mycophenolate mofetil (MMF) and prednisolone. Primary outcomes were the content of post-transplant microchimerism and its relation with acute rejection episodes and allograft function. Secondary outcomes were the presence of anti-HLA antibodies, serum levels of sCD30, IFN- $\gamma$  and IL-10 and their association with clinical manifestation and microchimerism levels during two years follow-up period.

#### General information

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT201106266876N1**

Registration date: **2011-06-27, 1390/04/06**

Registration timing: **retrospective**

Last update:

Update count: **0**

##### Registration date

2011-06-27, 1390/04/06

##### Registrant information

###### Name

Ghasem Solgi

###### Name of organization / entity

AJUMS

###### Country

Iran (Islamic Republic of)

###### Phone

+98 61 1374 8747

###### Email address

solgi@razi.tums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

Vice chancellor for research, Tehran University of Medical Sciences

##### Expected recruitment start date

2006-01-01, 1384/10/11

##### Expected recruitment end date

2008-01-01, 1386/10/11

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effect of donor bone marrow cells infusion on chimerism and prognosis of kidney allograft outcomes.

##### Public title

The role of chimerism in organ transplantation

##### Purpose

Prevention

## Inclusion/Exclusion criteria

Inclusion criteria: Being the case of first renal transplantation  
Exclusion criteria: Previous transfusion; retransplantation; cardiovascular diseases; having genetic diseases and morbid obesity.

## Age

From **25 years** old to **55 years** old

## Gender

Both

## Phase

N/A

## Groups that have been masked

*No information*

## Sample size

Target sample size: **40**

## Randomization (investigator's opinion)

Randomized

## Randomization description

## Blinding (investigator's opinion)

Not blinded

## Blinding description

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

The Ethics Committee, Tehran University of Medical Sciences

##### Street address

Ghods st., Keshavarz blv.

##### City

Tehran

##### Postal code

#### Approval date

2005-03-10, 1383/12/20

#### Ethics committee reference number

2023

## Health conditions studied

### 1

#### Description of health condition studied

Kidney allograft recipients

#### ICD-10 code

N19

#### ICD-10 code description

Unspecified renal failure

## Primary outcomes

### 1

#### Description

Serum creatinine levels

#### Timepoint

Weekly in first 3 month and then monthly during two years follow-up

#### Method of measurement

Colorimetric method (Jaffe)

### 2

#### Description

Microchimerism quantification

#### Timepoint

Weeks: 1 and 2; months: 1, 3, 6 and 12

#### Method of measurement

Real-time PCR

### 3

#### Description

Acute rejection episodes

#### Timepoint

During 6 months after transplantation

#### Method of measurement

Clinical evaluation and biopsy protocol

## Secondary outcomes

### 1

#### Description

sCD30

#### Timepoint

Days: 4, 14 and 30 after transplant

#### Method of measurement

ELISA method

### 2

#### Description

Anti-HLA antibodies

#### Timepoint

Second week; months: 1 and 3

#### Method of measurement

ELISA method

### 3

#### Description

Sera cytokines (IL-10 and IFN-g)

#### Timepoint

Days: 10 and 14 after transplant

#### Method of measurement

ELISA method

## Intervention groups

## 1

### Description

The intervention group: 20 patients who received donor bone marrow cells infusion concurrent with their kidney allograft (DBMI group). triple drug regimen for all patients include cyclosporine A (6mg/kg/day BD), mycophenolate mofetil (MMF) (2 gr/day BD) and prednisolone (2 mg/kg/day). Donor bone marrow cells were obtained from iliac crest by aspiration of 150-200 milliliters of bone marrow specimen at the time of donor nephrectomy. Afterwards, mononuclear cells of those samples were isolated using hydroxyethyl starch (HES 6%). One-half ml aliquots of MNCs suspension in HES were analyzed for absolute count of total nucleated cells, and flowcytometric determination of percentage and absolute number of CD34+ CD45+ hematopoietic progenitor cells . The average volume of donor cells which infused immediately post-operatively was 100-150 ml of mononuclear cells / recipient.

### Category

Other

## 2

### Description

The control group: 20 patients who received kidney allograft only. triple drug regimen for all patients include cyclosporine A (6mg/kg/day BD), mycophenolate mofetil (MMF) (2 gr/day BD) and prednisolone (2 mg/kg/day).

### Category

Treatment - Other

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Sina hospital, Tehran University of Medical Sciences

##### Full name of responsible person

Dr. Gholamreza Pourmand

##### Street address

Urology research center, Sina hospital, Imam khomeini str.

##### City

Tehran

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Vice chancellor for research, Tehran University of Medical Sciences

##### Full name of responsible person

Dr. Akbar Fotouhi

##### Street address

Ghods St., Keshavarz Blv.

##### City

Tehran

#### Grant name

#### Grant code / Reference number

2023

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Vice chancellor for research, Tehran University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

empty

#### Domestic or foreign origin

empty

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

empty

## Person responsible for general inquiries

### Contact

#### Name of organization / entity

Immunology dept, School of medicine, AJUMS, Ahvaz, Iran

#### Full name of responsible person

Dr. Ghasem Solgi

#### Position

Assistant professor

#### Other areas of specialty/work

#### Street address

Immunology dept, School of medicine, AJUMS, Golestan st., Ahvaz, Iran

#### City

Ahvaz

#### Postal code

#### Phone

+98 61 1374 8747

#### Fax

#### Email

solgi@razi.tums.ac.ir ghsolgi2@yahoo.com

#### Web page address

## Person responsible for scientific inquiries

### Contact

#### Name of organization / entity

Molecular Immunology Research Center, Tehran University of Medical Sciences

#### Full name of responsible person

Dr. Ali Akbar Amirzargar

#### Position

Professor

#### Other areas of specialty/work

#### Street address

Building No.7, School of medicine, Poursina Ave

#### City

Tehran

#### Postal code

**Phone**

+98 21 6443 2465

**Fax**

+98 21 6641 9536

**Email**

amirzara@sina.tums.ac.ir

**Web page address****Postal code****Phone****Fax****Email**

ghsolgi2@yahoo.com

**Web page address****Person responsible for updating data****Contact****Name of organization / entity**

Immunology Dept, School of medicine, AJUMS, Ahvaz,  
Iran

**Full name of responsible person**

Dr. Ghasem Solgi

**Position**

Assistant professor

**Other areas of specialty/work****Street address**

Immunology Dept, School of medicine, AJUMS,  
Golestan str.

**City**

Ahvaz

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

*empty*

**Study Protocol**

*empty*

**Statistical Analysis Plan**

*empty*

**Informed Consent Form**

*empty*

**Clinical Study Report**

*empty*

**Analytic Code**

*empty*

**Data Dictionary**

*empty*